PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Announces the Filing of New Patent Application for Thykamine^TM

Quebec, Quebec – November 16, 2017  –Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, today announced that the Corporation has filed a patent application for Thykamine™ use in cardiovascular diseases.

The patent application covers the use of Thykamine™ for the prevention and/or treatment of cardiovascular diseases. Cardiovascular diseases include several diseases associated with inflammation of the cardiovascular system such as angina, stroke, myocardial/cerebral infarction, atherosclerosis, ischemia, rheumatic heart disease, cardiomyopathy, heart arrhythmia, peripheral artery disease, venous thrombosis, unstable angina, and arterial revascularization.

“The filing of this new patent is yet another pivotal component of our broad strategy of expanding our already robust list of patents. Importantly, this filing is timely as we look to demonstrate the potential broad application of Thykamine™ as an anti-inflammatory drug” said Dr. André P. Boulet, President & CEO of Devonian.

About Thykamine^TM

Thykamine^TM, the first pharmaceutical product issued from Devonian’s SUPREX^TM platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine^TM have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis. Thykamine^TM is currently under development as treatment for ulcerative colitis and atopic dermatitis. Both Thykamine^TM and SUPREX^TM platforms are protected by several patents in North America, Europe and Asia.

About Devonian

Devonian is a clinical stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This focus is supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus those for traditional prescription medicines. Devonian is founded on a broad-based platform that spans more than fifteen years of research. Devonian’s proprietary process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae is known as: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREXTM). Thykamine™ is the first product derived from this platform. The potent anti-inflammatory and anti-oxidative active properties of Thykamine™ have been demonstrated in several pre-clinical studies as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information, visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

The post Devonian Announces the Filing of New Patent Application for Thykamine^TM appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine^TM in Adult patients with Mild-to-Moderate Atopic Dermatitis

Quebec, Quebec – November 9, 2017  – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, today announced the initiation of a Phase IIa clinical study to evaluate the tolerability, safety and efficacy Thykamine™, in adult patients with mild-to-moderate Atopic Dermatitis (AD). Thykamine™ is an innovative product with anti-inflammatory, anti-oxidative and immunomodulatory properties for the prevention and treatment of several life-altering health conditions

The randomized, double-blind, parallel-group, placebo-controlled study is being conducted at six (6) clinical centers in Canada.  Eligible adult patients with mild-to-moderate AD will receive one of 3 concentrations of Thykamine™ cream (0.05%, 0.1% and 0.25%) or placebo. The cream will be applied twice a day for 28 days to all areas of the skin that are affected by atopic dermatitis, excluding the palms, soles of the feet and scalp. “This Phase IIa study represents the first milestone of our Atopic Dermatitis clinical development program,” said Dr. André P. Boulet, President & CEO of Devonian. “We then look forward to beginning clinical trials with pediatric patients where managing the itchy skin and scratching caused by mild to moderate eczema is particularly challenging for parents and physicians.”

About Atopic Dermatitis (AD)

Atopic dermatitis (AD), also known as eczema, is a type of inflammation of the skin. It results in itchy, red, swollen, and cracked skin that may lead to secondary infection. The condition typically starts in childhood with changing severity over the years. Although the cause of AD is unknown, it is believed to involve genetics, a compromised immune system and can be triggered by environmental factors. AD is the most common skin disease¹.and its prevalence continues to increase worldwide. In the United States, the incidence has been reported to be 10-20% of children with new diagnoses at almost 11% per year². The severity of AD can be categorized into three stages, mild, moderate and severe. The mild and moderate forms constitute approximately 67% and 26% respectively of the AD childhood patient population. A similar distribution has been reported in the adult patient population (71% and 26% respectively) ^3,4. There is currently a high unmet need for new, effective and well-tolerated treatment options in AD⁵.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX^™ platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine™ have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis. Thykamine™ is currently under development as treatment for ulcerative colitis and atopic dermatitis. Both Thykamine™ and SUPREX™ platforms are protected by several patents in North America, Europe and Asia.

About Devonian

Devonian is a clinical stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This focus is supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus those for traditional prescription medicines. Devonian is founded on a broad-based platform that spans more than fifteen years of research. Devonian’s proprietary process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae is known as: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX™). Thykamine™ is the first product derived from this platform. The potent anti-inflammatory and anti-oxidative active properties of Thykamine™ have been demonstrated in several pre-clinical studies as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information, visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

References

1. Peng W., Novak N. Pathogenesis of atopic dermatitis. Clinical et Experimental Allergy 2015, 45 : 566-574.
2. Eichenfield F, Ellis CN, Mancini AJ, Paller AS, Simpsom EL. Atopic Dermatitis: Epidemiology and Pathogeneses Update. Semin Cutan Med Surg 2012, Sep; 31 (3 Suppl): S3-5.
3. Silverberg JI, Simpson EL. Associations of childhood eczema severity: A US population based study. Dermatitis 2014; 25(3):107-114.
4. Chaplin S. Guide to treatments used for atopic dermatitis in adults. Prescriber 2016: 27(10): 30-39.
5. Leung DYM. Guttman-Yassky E. Assessing the current treatment of atopic dermatitis: Unmet needs. J. of Allergy and Clinical Immunology. 2017; 139(4) Suppl.: S47-48

The post Devonian Announces Initiation of Phase IIa Clinical Trial of Thykamine^TM in Adult patients with Mild-to-Moderate Atopic Dermatitis appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Health Announces Purgenesis^TM anti-aging
treatment marketing and distribution partnership.

Quebec, Quebec – September 28, 2017  – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and derma-cosmeceutical products, today announced that it has signed its first exclusive marketing and distribution agreement with Altius Healthcare Inc. (‘‘Altius’’) to distribute its proprietary Purgenesis^TM anti-aging treatment in Canada.

The exclusive distribution agreement includes upfront payment for each treatment as well as up to 25% royalties based on sales. Altius expects to launch the product in Q4 2017. The product, which was recently recognized by the Canadian Dermatology Association through its Skin Health Program^TM, will be made exclusively available through certified Canadian dermatologists.

“This partnership marks an important milestone for Devonian.  After almost fifteen years invested in research and development, this is our first clinically-proven derma-cosmeceutical product to reach the commercialization stage,  Altius’ expertise in pharmaceutical marketing and its founders’ long standing relationship with physicians support our vision of building a strong franchise with healthcare professionals.”, said Dr Andre P. Boulet, President and Chief Executive Officer of Devonian.

“We are proud to include Devonian as one of our partners fuelling our product pipeline in Canada. Purgenesis^TM anti-aging treatment was developed under pharmaceutical standards, therefore, supported by data resulting from clinical studies. Thus, Purgenesis^TM anti-aging treatment is an ideal complement to our Dermatology portfolio. “, stated Sybil Dahan, President of Altius.

 About Purgenesis^TM anti-aging treatment

Purgenesis^TM anti-aging treatment has three components: a day cream, a night cream and an eye cream. These creams contain R-Spinasome® complex, an active structure with anti-oxydant properties. The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate  noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides RSpinasome® complex with unprecedented, long-lasting anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to evaluate the performance of Purgenesis^TM Anti-aging product line compared with two other leading prestige brands over a 28-day period of use. The results indicate that Purgenesis^TM anti-aging line is significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration effects. Purgenesis^TM anti-aging treatment is patent-pending worldwide with the exception of Japan where a patent was issued (#JP 5952261). The product has been accredited by the Canadian Dermatology Association under their Skin Health Program^TM.

About Altius Healthcare Inc.

As a uniquely Canadian pharmaceutical company, Altius Healthcare’s mission is to provide healthcare products designed to help people of all ages live healthier lives. Its team’s diverse experience draws from nearly 40 years in producing, importing, marketing and distributing branded and generic medicines, as well as medical devices and natural health products. They are Canadian and understand Canada’s pharmaceutical industry. They know how to get things done in this highly regulated marketplace. They can bring products to the market and assure they succeed here. With a commitment to helping all Canadians live healthier lives, their priority is to introduce safe new healthcare products to the Canadian marketplace. They achieve this through strategic partnerships that link proven medicines, leading-edge technologies, and their ability to serve the needs of patients and healthcare professionals.

For more information about Altius Healthcare Inc., visit www.altiushealthcare.ca

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX™). The “Thykamine™” is the first product issued from this platform. The potent antiinflammatory and anti-oxidative activities of “Thykamine™” have been demonstrated in several preclinical experiments as well as in a Phase 2a “proof of concept” clinical study in patients with mild-tomoderate distal ulcerative colitis. The product is now moving into large phase 2 clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value dermacosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post Devonian Health Announces Purgenesis^TM anti-aging treatment marketing and distribution partnership. appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Health Group to present at GCFF (Global Chinese Financial Conference) 18^th annual conference.

Quebec, Quebec – September 12, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSX VENTURE: GSD) a clinical stage botanical pharmaceutical corporation, today announced that the Company’s President and Chief Executive Officer, Dr. Andre P. Boulet, will present an overview of the Company at the upcoming GCFF 18^th Annual Conference on Saturday, September 30^th at the Courtyard & Towneplace Suites, 7095 Woodbine Avenue, Markham, Ontario.

“We are pleased to participate in this world class conference that will allow us to share our recent developments and explore potential trade avenues with a respected group of Chinese stakeholders. With the recent announcement of the Canadian Dermatology Association’s recognition of our first product in the commercialization phase and the evolution of our botanical prescription drug pipeline, it is timely to develop our commercial and financial relationships both in North America and Asia,” said Dr. Andre Boulet, President and Chief Executive Officer of Devonian.

About the Conference

Held in the heart of the GTA’s Chinese community, the Global Chinese Financial Forum (GCFF) Toronto Conference 2017 will bring together the Chinese investors and public companies, market experts and financial service providers for one day of networking, presentations and knowledge sharing. With continued activity in the growing life science and tech sectors, the market is ripe with opportunities to invest. The conference will showcase investment opportunities in key sectors of Life Science, Technology, Mining and Oil & Gas.

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post Devonian Health Group to present at GCFF (Global Chinese Financial Conference) 18th annual conference appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Health Group’s Purgenesis™ anti-aging derma-cosmeceutical treatment is now recognized through the Canadian Dermatology Association Skin Health Program

Québec, Québec – September 6, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXV: GSD) a clinical stage botanical pharmaceutical corporation, is pleased to announce that its Purgenesis™ anti-aging three-cream treatment is now recognized by the Canadian Dermatology Association (CDA) through its Skin Health Program.

‘‘Devonian’s mission is to develop innovative products that contribute to people’s well being. Skin being the largest organ of the human body, it requires special care like any other organ. Devonian develops its dermo-cosmeceutical products with the highest pharmaceutical standards.  We cooperate with health-care professionals to bring added-value products to people. Purgenesis™ treatment can now bear the Skin Health Program seal of recognition, awarded after a thorough review of our treatment formulation by the CDA Skin Health Expert Advisory Board” states Dr Andre P. Boulet, PhD, President & CEO of Devonian.

“The CDA welcomes the addition of Purgenesis™ treatment to the Skin Health Program, a program that identifies products that are fragrance-free or unscented, have a low potential for irritation and do not contain the most common contact allergens” says Dr Ian Landells, certified Dermatologist and Chair of the Skin Health Program.

‘‘The Purgenesis™ brand should be marketed in Canada exclusively through certified dermatologists’’ added Dr Boulet.

About Purgenesis™ anti-aging treatment

Purgenesis™ anti-aging treatment has three components: a day cream, a night cream and an eye cream. These creams contain R-Spinasome® complex, an active structure extracted from organic baby spinach.  The structure of this complex is critical to its function as an anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species (ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this dynamism and capacity to regenerate that provides R-Spinasome® complex with unprecedented, long-lasting anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to evaluate the performance of Purgenesis™ Anti-aging product line compared with two other leading prestige brands over a 28-day period of use.  The results indicate that Purgenesis™ anti-aging line is significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration effects. Purgenesis™ anti-aging treatment is patent-pending worldwide with the exception of Japan where a patent was issued (#JP 5952261).

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development pathway versus traditional prescription medicines. Devonian is based on a broad-based platform originating from over ten years of research. This platform provides a unique process of extraction, purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology (SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business, Devonian is also involved in the development of high value derma-cosmeceutical products as part of a secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
 

The post Devonian Health Group’s Purgenesis™ anti-aging derma-cosmeceutical treatment is now recognized through the Canadian Dermatology Association Skin Health Program appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Health Group Announces Closing of Private
Placement.

Québec, Québec – July 12, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“)
(TSXV: GSD) a clinical stage botanical pharmaceutical corporation, is pleased to announce that it has
closed a non-brokered private placement (the “Offering“) by issuing 173,500 units (“Units“) at a price of
$0.75 per Unit for aggregate gross proceeds of $130,125. Each Unit consists of one subordinate voting
share and one-half of one share purchase warrant (each whole share purchase warrant, a “Warrant”).
Each Warrant will entitle its holder to purchase one subordinate voting share, at a price of $1.10, until July
12, 2019.

The proceeds of the Offering will be used for general working capital purposes.

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and
anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as
well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now
moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis.
While the development of prescription botanical drugs is its core business, Devonian is also involved in
the development of high value derma-cosmeceutical products as part of a secondary strategy to generate
short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES CLOSING OF PRIVATE PLACEMENT appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Announces Grant of Options.

QUEBEC, Québec – July 07, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation“)
(TSXV: GSD) announces that the Board of Directors has approved the grant of options (the ‘‘Options’’) to
purchase common shares in the capital of the Corporation. Such options are exercisable at a price of
$0.60 and for a period of five years from the date of grant. An aggregate of 860,000 options was granted
to certain directors and consultants of the Corporation. Such options vest on the grant date.

Additionally, the Company has granted 300,000 stock options to managements and employees of the
Corporation. Twenty-five (25%) of these granted options vest on the grant date and then 25% yearly over
the following years.

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and
anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as
well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now
moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis.
While the development of prescription botanical drugs is its core business, Devonian is also involved in
the development of high value derma-cosmeceutical products as part of a secondary strategy to generate
short-term revenues and optimize manufacturing efficiency.

For more information about Devonian Health Group Inc., visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES GRANT OF OPTIONS appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Announces Plans for its Dermatology program
of Thykamine™.

QUEBEC, Québec – June 22, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation”)
(TSXV: GSD) today announces key study design details for its planned Phase IIa clinical study of lead
product candidate, Thykamine™, in patients with mild-to-moderate Atopic Dermatitis (AD). The
Corporation also announces that JSS Medical Research Inc. has been selected as the Clinical Research
Organization (CRO) to oversee its Phase IIa clinical study.

This will be a multicenter, randomized, double-blind, parallel-group, vehicle-controlled (placebocontrolled)
study. Ninety-two (92) patients with mild-to-moderate AD will be included in this study. Eligible
patients will be randomized to receive either one of 3 concentrations of Thykamine™ cream (0.05%, 0.1%
and 0.25%) or vehicle (placebo). The cream will be applied twice a day to all AD affected areas of the
skin excluding the palms, soles and scalp, for 28 days. The planned study start date is end of June 2017.

“Our clinical program involving Thykamine™ is expanding as this therapeutic product is moving into more
advanced stages of clinical development. This Phase IIa study represents the first phase of our program
targeting dermatological applications for this innovative botanical drug’’ said Dr. André P. Boulet,
President & CEO of the Corporation.

“We are honored and excited that Devonian has selected JSS Medical Research as its partner in this
innovative program. It is encouraging to see that novel, efficient and better tolerated treatments are
emerging for chronic conditions, addressing an increasingly unmet need. As an academic clinical
researcher and epidemiologist, I was impressed with the high standards and scientific rigor that Devonian
has applied in the development of its therapeutic products and its leadership in transforming botanicals
into pharmaceuticals. Furthermore, I am proud to be part of this initiative that is further testimony to the
fact that Quebec and Canada are indeed major hubs for innovation and discovery in the health sciences”
said Dr. John Sampalis, President & CSO of JSS Medical Research Inc.

About Atopic Dermatitis (AD)

Atopic dermatitis (AD), also known as eczema, is a type of inflammation of the skin. It results in itchy, red,
swollen, and cracked skin. The condition typically starts in childhood with changing severity over the
years. The cause is unknown but believed to involve genetics, a compromised immune system and
environmental exposures. AD is the most common skin disease¹. AD prevalence continues to increase
worldwide. In the United States, prevalence has been reported to be 10-20% in children and new
diagnoses at almost 11% per year². The severity of AD can be categorized into mild, moderate and
severe. The mild and moderate forms constitute approximately 67% and 26% respectively of the AD
childhood patient population. A similar distribution has been reported in the adult patient population (71%
and 26% respectively) ^3,4. There is currently a high unmet need for new, effective and well-tolerated
treatment options in AD⁵.

About Thykamine™

Thykamine™, the first pharmaceutical product issued from Devonian’s SUPREX™ platform is a highly
innovative product to be used in the prevention and treatment of health conditions related to inflammation
and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, skin
aging, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory
properties of Thykamine™ have been demonstrated by an impressive number of in vitro and in
vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative
colitis. Thykamine™ is currently under development as treatment for ulcerative colitis and atopic
dermatitis. Both Thykamine™ and SUPREX™ platform are protected by several patents in North
America, Europe and Asia.

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory and
anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments as
well as in a clinical study in patients with mild-to-moderate distal ulcerative colitis. The product is now
moving into large phase II clinical trials in two therapeutic areas: Ulcerative Colitis and Atopic Dermatitis.
While the development of prescription botanical drugs is its core business, Devonian is also involved in
the development of high value derma-cosmeceutical products as part of a secondary strategy to generate
short-term revenues and optimize manufacturing efficiency.

For more information, visit www.groupedevonian.com.

About JSS Medical Research

JSS Medical Research is a full‐service International Contract Research Organization (CRO) with its
corporate office in Montreal, Canada, and regional offices in Colombia, Poland and India. The company
offers comprehensive clinical trial management services from study design to publication of results, in
Phase I‐IV trials across a broad range of therapeutic areas. With science and clinical epidemiological
expertise at its core and early phase services of the highest quality adhering to industry standards, JSS
Medical Research is a leader in Post‐Approval Clinical Epidemiology Studies (PACES) including
Post‐Marketing Observational Studies, Health Outcomes Research (HEOR) and Health Economics.
Currently. JSS Medical Research is conducting research studies in over 21 countries around the world for
its clients that include the top 25 Pharmaceutical companies and Biotechnology/Device companies,
worldwide.

For more information, visit www.jssresearch.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21^st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES PLANS FOR ITS DERMATOLOGY PROGRAM OF THYKAMINE appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Announces Issuance of One New Key Patent
and the Granting of a Trademark.

QUEBEC, June 21, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD) a
clinical stage botanical pharmaceutical corporation, announces today that the U.S. Patent and Trademark
Office has recently issued Patent #9,555,068, entitled ‘‘Oral compositions and route of administration
for the delivery of a thylakoid extract’’. The patent covers the oral delivery of thylakoid extract for
treating or preventing a disease or disorder involving the formation of reactive oxygen species and
inflammation in individuals. The patent also covers the use of thylakoids as a food or a food supplement,
as a pellet, as encapsulated granules or powder.

“We are very excited to have received additional patent protection covering oral delivery of thylakoids.
The new patent covers several delivery formulations of thylakoids, the active ingredient of our lead
product Thykamine™,” said Dr Andre P. Boulet, President & CEO of Devonian”

The Corporation also announces that the U.S. Patent and Trademark Office has recently granted a
trademark for R-Spinasome®, the active ingredient of its Purgenesis™ derma-cosmetic products.

“The granting of a trademark to R-Spinasome®, the active ingredient of our Purgenesis™ anti-aging
treatment (patent-pending), has a significant impact within our Intellectual Property (IP) strategy. Our IP
strategy includes patents and trademarks as a pair in order to provide higher economic value to our
shareholders. We apply this strategy to our pharmaceutical and derma-cosmeceutical programs. ’’ adds
Dr. Boulet.

About ThykamineTM

ThykamineTM, the first pharmaceutical product issued from Devonian’s SUPREXTM platform is a highly
innovative product to be used in the prevention and treatment of health conditions related to inflammation
and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, skin
aging, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory
properties of ThykamineTM have been demonstrated by an impressive number of in vitro and in
vivo studies as well as in a Phase 2a clinical study in patients with mild-to-moderate distal ulcerative
colitis. ThykamineTM is currently under development for ulcerative colitis and atopic dermatitis. Both
ThykamineTM and SUPREXTM platform are protected by several patents in North America, Europe and
Asia.

About PurGenesis™ anti-aging treatment

PurGenesis™ anti-aging treatment has three components: a day cream, a night cream and an eye
cream. These creams contain R-Spinasome® complex, an active structure of pigments, proteins and
lipids extracted from organic baby spinach. The structure of this complex is critical to its function as an
anti-oxidant, enabling it to capture and dissipate noxious energy generated by Reactive Oxygen Species
(ROS), returning the complex to a state where it is ready to undergo new activation cycles. It is this
dynamism and capacity to regenerate that provides R-Spinasome® complex with unprecedented, longlasting
anti-oxidant activity. A clinical study involving 72 subjects (aged 35-72years) was conducted to
evaluate the performance of Purgenesis™ Anti-aging product line compared with two other leading
prestige brands over a 28 day period of use. The results indicate that PurGenesis™ anti-aging line is
significantly superior than leading prestige brands in terms of its anti-wrinkle, firmness and hydration
effects. PurGenesis™ anti-aging treatment is patent-pending worldwide with the exception of Japan
where a patent was issued (#JP 5952261).

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). The “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory
and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments
as well as in a Phase 2a “proof of concept” clinical study in patients with mild-to-moderate distal ulcerative
colitis. The product is now moving into large phase 2 clinical trials in two therapeutic areas: Ulcerative
Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business,
Devonian is also involved in the development of high value derma-cosmeceutical products as part of a
secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The post DEVONIAN HEALTH GROUP INC.- DEVONIAN ANNOUNCES ISSUANCE OF ONE NEW KEY PATENT AND THE GRANTING OF A TRADEMARK appeared first on DEVONIAN HEALTH GROUP INC..

PRESS RELEASE
For immediate release

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Devonian Announces the appointment of two new
members to the Board of Directors and Senior
Management Changes to support Growth Strategy.

QUEBEC, MAY 31st, 2017 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD)
today announced the nomination of Mr. Jacques Bernier, BPharm., MBA and Dr. Louis Flamand, PhD.
effective as of May 30th, 2017.

“As Devonian progresses, rapidly within its pharmaceutical program, the time has come to expand the
Board of Directors to ensure the Corporation achieves its goals. The Devonian’s Board of Directors is
extremely pleased to be welcoming Mr. Jacques Bernier and Dr. Louis Flamand as directors of the
Corporation. They bring with them a wealth of Pre-clinical and pharmaceutical experience that enhances
the bench strength of the Board of Directors” said Dr. André P. Boulet, President and Chief Executive
Officer of the Corporation.

From 2008 until 2014, Mr. Bernier was CEO of Folia Biotech Inc. (“Folia”), a clinical stage
biopharmaceutical corporation focused on exploiting its proprietary immune-therapeutic platform to bring
to market therapeutic products in oncology and certain infectious diseases. During his tenure, he has
concluded several business partnerships that have strengthened the development of Folia’s technology.
Prior to joining Folia, Mr. Bernier acquired a broad management experience as the owner of a group of
pharmacies and as a member of the Board of Directors of various pharmaceutical corporations. He has a
profound understanding of the pharmaceutical industry and an acute experience in business
development.

Dr. Flamand is a full professor and vice-chair of the department of microbiology-infectious-diseaseimmunology
at the Faculty of medicine, Université Laval and senior researcher in the division of infectious
and immune diseases at the CHU de Quebec research center. Before joining Laval University,
Dr. Flamand obtained his PhD at the University of Montreal and post-doctoral training at the National
Institutes of Health and at the Institute of Human Virology (Maryland, USA). He received his MBA in
pharmaceutical management from Université Laval. Since 2008, he is President of the biohazards risk
committee at Université Laval. He is also member of the HHV-6 Foundation scientific advisory board
since 2006. Dr. Flamand has experience in pre-clinical development. Throughout his career, Dr. Flamand
has received several competitive scholarship awards and continuous funding support from several
funding agencies for his work in virology. Dr. Flamand is the author of more than 80 peer-reviewed
publications and is lead Editor of the book “Human Herpesviruses HHV-6A, HHV-6B & HHV-7: Diagnosis
and Clinical Management” 3rd edition.

The Corporation also announced that as of May 30th, Mr. François Michaud will not be acting as Chief
Financial Officer of the Corporation. Ms. Colette Laurin, the Corporate’s Corporate Controller, will assume
Mr. Michaud’s responsibilities as the Corporation’s interim Chief Financial Officer. The Corporation also
announces Mr. Matt Peppler has resigned as a member of the Corporation’s Board of Directors.

Dr. André P. Boulet, commented, “On behalf of the management team and the Devonian’s Board of
Directors, I would like to thank Matt and François for their contribution to Devonian over the last two
years”.

About Devonian

Devonian is a late stage botanical pharmaceutical corporation with novel therapeutic approaches
targeting unmet medical needs. Devonian’s core strategy is to develop prescription botanical drugs. This
strategy is supported by US-FDA set of regulatory guidelines favouring a more efficient drug development
pathway versus traditional prescription medicines. Devonian is based on a broad-based platform
originating from over ten years of research. This platform provides a unique process of extraction,
purification, stabilization and conditioning of a molecular complex responsible for the photosynthetic
process in plants and algae: The Supra Molecular Complex Extraction and Stabilisation Technology
(SUPREX). The “Thykamine™” is the first product issued from this platform. The potent anti-inflammatory
and anti-oxidative activities of “Thykamine™” have been demonstrated in several pre-clinical experiments
as well as in a Phase 2a “proof of concept” clinical study in patients with mild-to-moderate distal ulcerative
colitis. The product is now moving into large phase 2 clinical trials in two therapeutic areas: Ulcerative
Colitis and Atopic Dermatitis. While the development of prescription botanical drugs is its core business,
Devonian is also involved in the development of high value derma-cosmeceutical products as part of a
secondary strategy to generate short-term revenues and optimize manufacturing efficiency.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s objectives, strategies and
businesses that involve risks and uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to
be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical and dermo-cosmeceutical
products, the availability of funds and resources to pursue R&D projects, the successful and timely
completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the
pharmaceutical and dermo-cosmeceutical industries, uncertainties related to the regulatory process and
general changes in economic conditions. You will find a more detailed assessment of the risks that could
cause actual events or results to materially differ from our current expectations in Devonian’s prospectus
dated April 21st, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we
cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.